Pharmaceutical News

RSS

Insilico Medicine's pan-TEAD inhibitor ISM6331 receives FDA IND clearance for mesothelioma treatment

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced ISM6331, potential best-in-class pan-TEAD inhibitor, has received the U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for the treatment of mesothelioma, following the grant of Orphan Drug Designation (ODD) in June 2024. It brings the total number of IND-approved molecules of Insilico to nine.

8 Aug 2024

Review reveals high rates of opioid dependence among chronic pain patients

A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers has found that nearly one in ten patients experiences opioid dependence or opioid use disorder and nearly one in three shows symptoms of dependence and opioid use disorder.

8 Aug 2024

How little Denmark got homegrown giant Novo Nordisk to lower ozempic prices

On May 13, Sen. Bernie Sanders (I-Vt.) published an open letter to Novo Nordisk on the front page of a leading Danish newspaper, urging the hometown company to live up to its altruistic standards by lowering U.S. prices for its blockbuster diabetes and weight loss drugs.

8 Aug 2024

Amyloid immunotherapy for early Alzheimer's: Promising but fraught with challenges

Researchers highlighted the complexities of using amyloid immunotherapy for early Alzheimer's disease, discussing its clinical benefits, challenges, and broader health implications. Despite some positive results, concerns over adverse effects, trial biases, and cost hinder widespread adoption.

7 Aug 2024

Recombinant shingles vaccine linked to lower dementia risk, especially in women

Study published in Nature Medicine found that the recombinant shingles vaccine is linked to a reduced risk of dementia. This protective effect was particularly notable in females, suggesting a potential advantage of the recombinant vaccine over the live vaccine.

7 Aug 2024

From discovery to approval: Vorasidenib approved by FDA for treatment of IDH-mutant gliomas

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA).

7 Aug 2024

FDA approves vorasidenib for Grade 2 gliomas with IDH mutations

Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations.

6 Aug 2024

Cambridge experts question efficacy and practicality of new amyloid immunotherapy drugs

Cambridge researchers have cast doubt on whether new amyloid immunotherapy drugs will have the desired effect of significantly reducing the impact of Alzheimer's disease.

6 Aug 2024

Enhancing nitrofurantoin solubility and bioavailability through solid dispersion formulation

Announcing a new article publication for BIO Integration journal. Nitrofurantoin is a BCS II drug with a low solubility and dissolution rate.

6 Aug 2024

Valproic acid shows promise in reducing COVID-19 severity and hospitalization

Researchers found that valproic acid (VPA), especially when combined with DHA, significantly reduces SARS-CoV-2 infection rates and severity, potentially activating antiviral mechanisms. Epidemiologic data support VPA's role in reducing COVID-19 severity and hospitalization rates.

6 Aug 2024

Study confirms cardiovascular safety of COVID-19 vaccines among millions of adults in England

A study confirms the cardiovascular safety of different COVID-19 vaccine doses, showing reduced risks of common cardiovascular events among vaccinated adults in England.

4 Aug 2024

Public insurance recipients less likely to receive diabetes and obesity drug, study reveals

A new USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with private insurance.

2 Aug 2024

FDA grants accelerated approval for first engineered T cell therapy to treat adults with synovial sarcoma

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.

2 Aug 2024

Researchers identify strategy to design safer opioids

Opioid medications offer people relief from debilitating pain, but these drugs come with dangers: the risk for addiction, miserable withdrawal symptoms and the potential for fatal overdose.

2 Aug 2024

Triptolide-based treatment prolongs symptom-free survival in preclinical medulloblastoma models

A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical medulloblastoma models – all without showing signs of toxicity.

1 Aug 2024

Groundbreaking method dmSLAY improves antimicrobial peptide effectiveness and safety

Researchers developed a high-throughput method, dmSLAY, to assess thousands of AMP variants, combining it with machine learning to enhance membrane selectivity and reduce toxicity.

1 Aug 2024

Aspirin may lower colorectal cancer risk for people with unhealthy lifestyles

Regular aspirin may help lower risk of colorectal cancer in people with greater lifestyle-related risk factors for the disease, according to a study led by researchers at Mass General Brigham.

1 Aug 2024

Anticancer drugs show promise in reducing Alzheimer's dementia risk

Study finds anticancer drugs, specifically antimetabolites and molecular targeted therapies, may reduce the risk of Alzheimer's type dementia but not vascular dementia.

1 Aug 2024

FDA clears UAB startup's TIX100 for clinical trials

The University of Alabama at Birmingham startup TIXiMED, Inc., has obtained clearance from the United States Food and Drug Administration to proceed to clinical trials under an Investigational New Drug for TIX100, its novel oral Type 1 diabetes drug.

31 Jul 2024

Commonly used anesthetic drug can restore the function of ion channel linked to epilepsy

Mutated variants of a particular ion channel cause difficult-to-treat epilepsy. A study published in the journal Nature now shows that a commonly used anesthetic drug, propofol, can restore the function of this ion channel.

31 Jul 2024

Previous
1
...
8
9
10
11
12
13
14
...
1433
Next

Pharmaceutical News

Insilico Medicine's pan-TEAD inhibitor ISM6331 receives FDA IND clearance for mesothelioma treatment

Review reveals high rates of opioid dependence among chronic pain patients

How little Denmark got homegrown giant Novo Nordisk to lower ozempic prices

Amyloid immunotherapy for early Alzheimer's: Promising but fraught with challenges

Recombinant shingles vaccine linked to lower dementia risk, especially in women

From discovery to approval: Vorasidenib approved by FDA for treatment of IDH-mutant gliomas

FDA approves vorasidenib for Grade 2 gliomas with IDH mutations

Cambridge experts question efficacy and practicality of new amyloid immunotherapy drugs

Enhancing nitrofurantoin solubility and bioavailability through solid dispersion formulation

Valproic acid shows promise in reducing COVID-19 severity and hospitalization

Study confirms cardiovascular safety of COVID-19 vaccines among millions of adults in England

Public insurance recipients less likely to receive diabetes and obesity drug, study reveals

FDA grants accelerated approval for first engineered T cell therapy to treat adults with synovial sarcoma

Researchers identify strategy to design safer opioids

Triptolide-based treatment prolongs symptom-free survival in preclinical medulloblastoma models

Groundbreaking method dmSLAY improves antimicrobial peptide effectiveness and safety

Aspirin may lower colorectal cancer risk for people with unhealthy lifestyles

Anticancer drugs show promise in reducing Alzheimer's dementia risk

FDA clears UAB startup's TIX100 for clinical trials

Commonly used anesthetic drug can restore the function of ion channel linked to epilepsy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News